<div id="readability-page-1"><p>Calamos Wealth Management LLC lifted its position in  Amgen Inc. (NASDAQ:AMGN - Free Report) by 136.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,813 shares of the medical research company's stock after purchasing an additional 3,351 shares during the period. Calamos Wealth Management LLC's holdings in Amgen were worth $1,640,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p><ul><li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li></ul><p>A number of other hedge funds have also recently added to or reduced their stakes in AMGN. Legacy Investment Solutions LLC purchased a new stake in shares of  Amgen during the 2nd quarter worth about $27,000.  CBIZ Investment Advisory Services LLC increased its stake in shares of  Amgen by 1,214.3% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company's stock valued at $29,000 after purchasing an additional 85 shares in the last quarter.  Evelyn Partners Investment Management LLP acquired a new position in  Amgen in the 2nd quarter worth about $32,000.  Howard Hughes Medical Institute acquired a new position in  Amgen in the 2nd quarter worth about $32,000.  Finally, Quaker Wealth Management LLC boosted its position in  Amgen by 200.0% during the second quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company's stock worth $34,000 after purchasing an additional 240 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors. </p><h2>Amgen Price Performance</h2><p>Shares of NASDAQ AMGN opened at $328.49 on Wednesday. The firm has a 50-day simple moving average of $324.05 and a 200-day simple moving average of $302.22. The company has a quick ratio of 0.99, a current ratio of 1.28 and a debt-to-equity ratio of 5.45. The stock has a market capitalization of $176.89 billion, a price-to-earnings ratio of 25.39, a price-to-earnings-growth ratio of 3.06 and a beta of 0.45. Amgen Inc. has a 52 week low of $257.05 and a 52 week high of $346.38. </p><ul><li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li></ul><p>Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, topping analysts' consensus estimates of $5.01 by $0.63. The firm had revenue of $9.56 billion for the quarter, compared to analyst estimates of $8.98 billion. Amgen had a net margin of 19.47% and a return on equity of 162.59%. Amgen's quarterly revenue was up 12.4% on a year-over-year basis. During the same period in the previous year, the business posted $5.58 earnings per share. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS.  On average, equities analysts predict that  Amgen Inc. will post 20.62 earnings per share for the current fiscal year. </p><h2>Amgen Increases Dividend</h2><p>The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be issued a $2.52 dividend. This is a boost from Amgen's previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, February 13th. Amgen's payout ratio is 73.57%. </p><h2>Insider Buying and Selling</h2><ul><li>Amgen Stock: New All-Time Highs Ahead After Earnings Beat</li></ul><p>In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of the firm's stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the sale, the senior vice president directly owned 7,225 shares of the company's stock, valued at $2,436,703.50. This trade represents a 30.29% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, EVP Murdo Gordon sold 6,879 shares of the business's stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the transaction, the executive vice president directly owned 41,923 shares in the company, valued at approximately $14,120,924.09. The trade was a 14.10% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 10,908 shares of company stock worth $3,674,966. 0.69% of the stock is owned by corporate insiders. </p><h2>Wall Street Analyst Weigh In</h2><p>AMGN has been the subject of a number of recent analyst reports. DZ Bank boosted their price objective on Amgen from $335.00 to $364.00 in a research report on Monday, November 10th. The Goldman Sachs Group  reissued a &#34;buy&#34; rating on shares of Amgen in a report on Tuesday, November 25th. HSBC  restated a &#34;buy&#34; rating and set a $425.00 price objective on shares of Amgen in a research report on Wednesday, December 10th. Raymond James Financial initiated coverage on shares of Amgen in a research note on Wednesday, September 3rd. They set a &#34;market perform&#34; rating for the company. Finally, Morgan Stanley reduced their price target on shares of Amgen from $329.00 to $304.00 and set an &#34;equal weight&#34; rating for the company in a research report on Friday, December 12th. One research analyst  has rated the stock with a Strong Buy rating, eleven have given a Buy rating, ten have given a Hold rating and one  has issued  a Sell rating to the company's stock. According to data from MarketBeat.com, Amgen currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $334.14.</p><p><b>View Our Latest Stock Analysis on AMGN</b></p><h2>Amgen Profile</h2> (Free Report)<p>Amgen Inc <span>NASDAQ: AMGN<span></span></span> is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.  </p><p>Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Amgen</li><li>Do not delete, read immediately</li><li>The Crash Has Already Started (Most Just Don’t See It Yet)</li><li>ALERT: Drop these 5 stocks before January 2026!</li><li>[No Brainer Gold Play]: “Show me a better investment.”</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Amgen Right Now?</h2><p>Before you consider Amgen, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p><p>While Amgen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AMGN

<p>Calamos Wealth Management LLC increased its stake in Amgen Inc. by 136.1% in Q3, owning 5,813 shares valued at $1.64 million. Other hedge funds also adjusted their positions in Amgen. The company reported Q3 earnings of $5.64 per share, exceeding estimates, with revenue of $9.56 billion. Amgen declared a quarterly dividend of $2.52, up from $2.38, with a yield of 3.1%. Insider selling occurred, with significant shares sold by executives. Amgen's stock performance shows a market cap of $176.89 billion and a P/E ratio of 25.39.</p>

Amgen Inc. $AMGN Shares Acquired by Calamos Wealth Management LLC